UTMB's international vaccine symposium to be held Feb. 7-9

NewsGuard 100/100 Score

An international vaccine symposium sponsored by the University of Texas Medical Branch at Galveston and scheduled for Feb. 7-9 will reflect a dramatic shift in the world of vaccinology, according to Alan Barrett, director of UTMB's Sealy Center for Vaccine Development.

"In the 20th century, vaccination was about helping children survive to adulthood by protecting them from infectious diseases," Barrett said. "In the 21st century, vaccination will be about helping adults live longer by stopping chronic diseases, and we've organized this conference around that theme."

About 130 researchers are expected to attend the symposium, which will be held at Galveston's Moody Gardens Hotel, Spa and Convention Center. Conference speakers will discuss the development of vaccines for addiction, cancer, chronic infectious diseases and neurodegenerative diseases.

"We're going to have presentations by leaders in a wide variety of fields - experts on vaccines against addiction to tobacco and other drugs, a representative from the CDC to talk about progress on HIV vaccines, investigators working on cancer vaccines, and researchers developing vaccines to protect against Alzheimer's disease," Barrett said. "Chronic diseases are the new frontier for vaccines, and this symposium will give us a really exciting opportunity to explore this area in depth."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Nigeria first to rollout new Men5CV vaccine against meningitis